← Back to list
Announcement Details analyzed
ID
295
Seq No
106567175
Symbol
BALAXI
Company
BALAXI PHARMACEUTICALS LIMITED
Subject
Change in Management
Category
Change in Management
Description
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management
Ann. Date
2026-03-25 13:12:02
Dissemination
25-Mar-2026 13:12:02
Attachment
📄 Download PDF BALAXI_25032026131145_Outcome_of_Board_Meeting.pdf
Created
2026-03-25T07:54:08.763Z
Updated
2026-03-25T10:10:42.948Z
AI Analysis claude-cli
High Impact Event
Company
Balaxi Pharmaceuticals Limited
Event
Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer w.e.f. 25th March, 2026
Time
25th March, 2026 (Board meeting: 11:45 a.m. – 12:50 p.m. IST)
Key Insight

Balaxi Pharmaceuticals has filled the Company Secretary and Compliance Officer role with Mr. Aman Purohit, an ICSI Associate Member (Membership No. A59345) with 6 years of post-qualification experience. His background spans M&A, corporate restructuring, fund-raising, and due diligence across sectors, with prior stints at Patil Rail Infrastructure and Re Sustainability IWM Solutions, both based in Hyderabad.

Why it Matters

Appointment of a compliance officer is a regulatory necessity under SEBI's LODR norms, and any vacancy in this role carries governance risk. The hire signals that Balaxi is shoring up its compliance infrastructure, which is particularly relevant for a small-cap pharma company (₹97.17 Cr market cap) under increased SEBI scrutiny. Investors should view this as a routine governance positive rather than a strategic catalyst.

Market Cap
₹97.17 Cr
Sector
Pharmaceuticals
Source
NSE Corporate Announcement
Link
NSE Announcements
Confidence Score
3/10
High impact event
  - Company Name: Balaxi Pharmaceuticals Limited
  - Event: Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer w.e.f. 25th March, 2026
  - Time: 25th March, 2026 (Board meeting: 11:45 a.m. – 12:50 p.m. IST)

Key Insight: Balaxi Pharmaceuticals has filled the Company Secretary and Compliance Officer role with Mr. Aman Purohit, an ICSI Associate Member (Membership No. A59345) with 6 years of post-qualification experience. His background spans M&A, corporate restructuring, fund-raising, and due diligence across sectors, with prior stints at Patil Rail Infrastructure and Re Sustainability IWM Solutions, both based in Hyderabad.

Why it matters: Appointment of a compliance officer is a regulatory necessity under SEBI's LODR norms, and any vacancy in this role carries governance risk. The hire signals that Balaxi is shoring up its compliance infrastructure, which is particularly relevant for a small-cap pharma company (₹97.17 Cr market cap) under increased SEBI scrutiny. Investors should view this as a routine governance positive rather than a strategic catalyst.

Market cap: ₹97.17 Cr
sector: Pharmaceuticals
confidence score: 3

Source: NSE Corporate Announcement
Link: https://www.nseindia.com/companies-listing/corporate-filings-announcements